144 related articles for article (PubMed ID: 36523794)
1. The O
Salah S; Naser W; Jaber O; Saleh Y; Mustafa R; Abuhijlih R; Abuhijla F; Ismaeel T; Yaser S; Sultan I; Mustafa N; Tbakhi A
Rep Pract Oncol Radiother; 2022; 27(5):759-767. PubMed ID: 36523794
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
3. Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy.
Pretz JL; Barysauskas CM; George S; Hornick JL; Raut CP; Chen YE; Marcus KJ; Choy E; Hornicek F; Ready JE; DeLaney TF; Baldini EH
Oncologist; 2017 Oct; 22(10):1265-1270. PubMed ID: 28550026
[TBL] [Abstract][Full Text] [Related]
4. Correlation of commercially available quantitative
Dovek L; Nguyen NT; Ozer BH; Li N; Elashoff RM; Green RM; Liau L; Nghiemphu PL; Cloughesy TF; Lai A
Neurooncol Pract; 2019 May; 6(3):194-202. PubMed ID: 31386024
[TBL] [Abstract][Full Text] [Related]
5. O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications.
Kang SH; Park KJ; Kim CY; Yu MO; Park CK; Park SH; Chung YG
J Neurooncol; 2011 Feb; 101(3):477-86. PubMed ID: 20556478
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of
Lam K; Eldred BSC; Kevan B; Pianka S; Eldred BA; Zapanta Rinonos S; Yong WH; Liau LM; Nghiemphu PL; Cloughesy TF; Green RM; Lai A
Neurooncol Adv; 2022; 4(1):vdac030. PubMed ID: 35386566
[TBL] [Abstract][Full Text] [Related]
7. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Morandi L; Franceschi E; de Biase D; Marucci G; Tosoni A; Ermani M; Pession A; Tallini G; Brandes A
BMC Cancer; 2010 Feb; 10():48. PubMed ID: 20167086
[TBL] [Abstract][Full Text] [Related]
9. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A
JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793
[TBL] [Abstract][Full Text] [Related]
10. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
11. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
12. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
14. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F
J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820
[TBL] [Abstract][Full Text] [Related]
15. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
16. O
Bobola MS; Alnoor M; Chen JY; Kolstoe DD; Silbergeld DL; Rostomily RC; Blank A; Chamberlain MC; Silber JR
BBA Clin; 2015 Jun; 3():1-10. PubMed ID: 25558448
[TBL] [Abstract][Full Text] [Related]
17. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
18. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
19. Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O
Sharma M; Bellamkonda S; Mohapatra S; Meola A; Jia X; Mohammadi A; Angelov L; Barnett GH; Vogelbaum M; Ahluwalia MS
World Neurosurg; 2018 Aug; 116():e147-e161. PubMed ID: 29709748
[TBL] [Abstract][Full Text] [Related]
20. MGMT Methylation and Differential Survival Impact by Sex in Glioblastoma.
Barnett AE; Ozair A; Bamashmos AS; Li H; Bosler DS; Yeaney G; Ali A; Peereboom DM; Lathia JD; Ahluwalia MS
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611052
[No Abstract] [Full Text] [Related]
[Next] [New Search]